NCT04982705 is a Phase 1 clinical trial of [Part 1.1] IDG-16177 in Type 2 Diabetes, sponsored by IlDong Pharmaceutical Co Ltd.

Who is sponsoring NCT04982705?

NCT04982705 is sponsored by IlDong Pharmaceutical Co Ltd.

What drugs are being tested in NCT04982705?

Interventions in NCT04982705: [Part 1.1] IDG-16177, [Part 1.1] Placebo of IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177, [Part 2] IDG-16177, [Part 1.2] Placebo of IDG-16177, [Part 2] Placebo of IDG-16177.

What condition does NCT04982705 study?

NCT04982705 studies Type 2 Diabetes.

Is NCT04982705 still recruiting?

NCT04982705 is currently status unknown. Last updated 11 August 2022.

Last reviewed 2022-08-11 · How we verify

NCT04982705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Status unknown Phase 1 Last updated 11 August 2022

What this trial tests

Phase 1 trial testing [Part 1.1] IDG-16177 in Type 2 Diabetes in 94 participants. Status unknown.

Timeline

7 July 2021

Primary endpoint
9 November 2022

30 December 2022

Quick facts

Lead sponsor	IlDong Pharmaceutical Co Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	94
Start date	7 July 2021
Primary completion	9 November 2022
Estimated completion	30 December 2022
Sites	1 location across Germany

Drugs / interventions tested

[Part 1.1] IDG-16177
[Part 1.1] Placebo of IDG-16177 — full drug profile →
[Part 2] Sitagliptin
[Part1.2] IDG-16177 — full drug profile →
[Part 2] IDG-16177 — full drug profile →
[Part 1.2] Placebo of IDG-16177 — full drug profile →
[Part 2] Placebo of IDG-16177 — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

IlDong Pharmaceutical Co Ltd — full company profile →

Who can join

Adults 19 to 70, male only, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in healthy male subjects and patients with T2DM at different dose levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders.
Guan HP, Xiong Y. · · 2022 · cited 12× · PMID 36386134 · DOI 10.3389/fphar.2022.1043828

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other IlDong Pharmaceutical Co Ltd trials

Trials by the same sponsor.

NCT06635226 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects · Phase 1 · recruiting
NCT06063291 — Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects · Phase 1 · completed
NCT05663879 — Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers · Phase 1 · unknown
NCT05604287 — Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects · Phase 1 · terminated
NCT05259020 — To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04982705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IlDong Pharmaceutical Co Ltd
Last refreshed: 11 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing